97 related articles for article (PubMed ID: 23302303)
1. [Importance of pathology research on lung adenocarcinoma].
Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):649-51. PubMed ID: 23302303
[No Abstract] [Full Text] [Related]
2. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
3. Bronchioloalveolar adenocarcinoma and pulmonary langerhans cell histiocytosis in a patient with MUTYH-associated polyposis.
von der Thüsen JH; van de Wetering MD; Westermann AM; Heideman DA; Thunnissen E
J Clin Oncol; 2011 Mar; 29(8):e188-90. PubMed ID: 21189386
[No Abstract] [Full Text] [Related]
4. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.
Kaira K; Horie Y; Ayabe E; Murakami H; Takahashi T; Tsuya A; Nakamura Y; Naito T; Endo M; Kondo H; Nakajima T; Yamamoto N
J Thorac Oncol; 2010 Apr; 5(4):460-5. PubMed ID: 20107421
[TBL] [Abstract][Full Text] [Related]
6. Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.
Lee CN; Chen HY; Liu HE
J Clin Oncol; 2010 Mar; 28(7):e111-2. PubMed ID: 20008635
[No Abstract] [Full Text] [Related]
7. Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features?
Glynn C; Zakowski MF; Ginsberg MS
J Thorac Oncol; 2010 Mar; 5(3):344-8. PubMed ID: 20087229
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
Smit EF; Dingemans AM; Thunnissen FB; Hochstenbach MM; van Suylen RJ; Postmus PE
J Thorac Oncol; 2010 May; 5(5):719-20. PubMed ID: 20421765
[No Abstract] [Full Text] [Related]
9. A 75-year-old man with progressive bronchioalveolar carcinoma.
Baikadi M; Lovly C; Horn L; Reckamp KL; Noonan K; Laskin J; Morris GJ
Semin Oncol; 2013 Feb; 40(1):e1-8. PubMed ID: 23391120
[No Abstract] [Full Text] [Related]
10. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread.
Chung JH; Choe G; Jheon S; Sung SW; Kim TJ; Lee KW; Lee JH; Lee CT
J Thorac Oncol; 2009 Dec; 4(12):1490-5. PubMed ID: 19844187
[TBL] [Abstract][Full Text] [Related]
12. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
[TBL] [Abstract][Full Text] [Related]
13. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H
J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438
[TBL] [Abstract][Full Text] [Related]
14. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
[TBL] [Abstract][Full Text] [Related]
15. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
16. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
17. [Molecular pathology of lung cancer: key to personalized medicine].
Cheng L; Li Y; Zhang SB; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):715-20. PubMed ID: 23302321
[No Abstract] [Full Text] [Related]
18. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
19. Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.
Thomas A; Xi L; Carter CA; Rajan A; Khozin S; Szabo E; Dennis PA; Giaccone G; Raffeld M
Clin Lung Cancer; 2013 Jul; 14(4):452-6. PubMed ID: 23540867
[No Abstract] [Full Text] [Related]
20. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]